Barry Kenny
Corporate Officer/Principal bij Heptares Therapeutics Ltd.
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Malcolm Weir | M | 65 |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | 17 jaar |
John Montana | M | - |
Metrion Biosciences Ltd.
Metrion Biosciences Ltd. BiotechnologyHealth Technology Metrion Biosciences Ltd. is a contract research organization that specializes in providing drug discovery services to pharmaceutical and bioscience customers. Metrion Biosciences is based in Great Abington, UK and was founded in 2015. The British company offers a range of high-quality ion channel assays on a fee-for-service or collaboration basis, including an industry-leading panel of in vitro cardiac ion channel safety assays, translational native cell and phenotypic assays for neurological and cardiotoxicity testing, and a range of other ion channel screening services such as cell line development and optimization. Andrew Southan has been the CEO of the company since 2016. | 3 jaar |
Tim Tasker | M | 71 |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | - |
Miles Congreve | M | - |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | 16 jaar |
Chris Cargill | M | 40 |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | 5 jaar |
Ed Hulme | M | - |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | - |
Beverly Lybrand | F | - |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | - |
Gebhard Schertler | M | - |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | - |
Tomohiro Tohyama | M | - |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Alastair Riddell | M | 74 |
Paradigm Therapeutics Ltd.
Paradigm Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Paradigm Therapeutics Ltd. discovers and develops drugs. The genomics-based drug discovery company uses research methods including model mouse genetics, bioinformatics and molecular biology to identify genes that serve as drug targets. The company has launched a subsidiary research center in Singapore. The company was founded in 1999 by Aparicio Samuel and Mark Carlton and is headquartered in Cambridge, UK. | 2 jaar |
Mark Carlton | M | - |
Paradigm Therapeutics Ltd.
Paradigm Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Paradigm Therapeutics Ltd. discovers and develops drugs. The genomics-based drug discovery company uses research methods including model mouse genetics, bioinformatics and molecular biology to identify genes that serve as drug targets. The company has launched a subsidiary research center in Singapore. The company was founded in 1999 by Aparicio Samuel and Mark Carlton and is headquartered in Cambridge, UK. | 8 jaar |
Jim Sutcliffe | M | - |
Paradigm Therapeutics Ltd.
Paradigm Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Paradigm Therapeutics Ltd. discovers and develops drugs. The genomics-based drug discovery company uses research methods including model mouse genetics, bioinformatics and molecular biology to identify genes that serve as drug targets. The company has launched a subsidiary research center in Singapore. The company was founded in 1999 by Aparicio Samuel and Mark Carlton and is headquartered in Cambridge, UK. | - |
Marc Rogers | M | - |
Metrion Biosciences Ltd.
Metrion Biosciences Ltd. BiotechnologyHealth Technology Metrion Biosciences Ltd. is a contract research organization that specializes in providing drug discovery services to pharmaceutical and bioscience customers. Metrion Biosciences is based in Great Abington, UK and was founded in 2015. The British company offers a range of high-quality ion channel assays on a fee-for-service or collaboration basis, including an industry-leading panel of in vitro cardiac ion channel safety assays, translational native cell and phenotypic assays for neurological and cardiotoxicity testing, and a range of other ion channel screening services such as cell line development and optimization. Andrew Southan has been the CEO of the company since 2016. | - |
Edwin Moses | M | 69 |
Paradigm Therapeutics Ltd.
Paradigm Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Paradigm Therapeutics Ltd. discovers and develops drugs. The genomics-based drug discovery company uses research methods including model mouse genetics, bioinformatics and molecular biology to identify genes that serve as drug targets. The company has launched a subsidiary research center in Singapore. The company was founded in 1999 by Aparicio Samuel and Mark Carlton and is headquartered in Cambridge, UK. | 3 jaar |
Alan Munro | M | - |
Paradigm Therapeutics Ltd.
Paradigm Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Paradigm Therapeutics Ltd. discovers and develops drugs. The genomics-based drug discovery company uses research methods including model mouse genetics, bioinformatics and molecular biology to identify genes that serve as drug targets. The company has launched a subsidiary research center in Singapore. The company was founded in 1999 by Aparicio Samuel and Mark Carlton and is headquartered in Cambridge, UK. | - |
Samuel Aparicio | M | - |
Paradigm Therapeutics Ltd.
Paradigm Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Paradigm Therapeutics Ltd. discovers and develops drugs. The genomics-based drug discovery company uses research methods including model mouse genetics, bioinformatics and molecular biology to identify genes that serve as drug targets. The company has launched a subsidiary research center in Singapore. The company was founded in 1999 by Aparicio Samuel and Mark Carlton and is headquartered in Cambridge, UK. | 8 jaar |
Mark William Keogh | M | 63 |
Metrion Biosciences Ltd.
Metrion Biosciences Ltd. BiotechnologyHealth Technology Metrion Biosciences Ltd. is a contract research organization that specializes in providing drug discovery services to pharmaceutical and bioscience customers. Metrion Biosciences is based in Great Abington, UK and was founded in 2015. The British company offers a range of high-quality ion channel assays on a fee-for-service or collaboration basis, including an industry-leading panel of in vitro cardiac ion channel safety assays, translational native cell and phenotypic assays for neurological and cardiotoxicity testing, and a range of other ion channel screening services such as cell line development and optimization. Andrew Southan has been the CEO of the company since 2016. | 2 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigd Koninkrijk | 17 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Barry Kenny
- Persoonlijk netwerk